Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Hamilton Researcher Wins Prestigious Mitacs Innovation Award for Breakthrough on Natural Fungi Compound
Dr. Timsy Bhando, a McMaster University researcher, won the Mitacs Innovation Award for discovering a novel fungi compound, KCB-100, with potential to treat neurodegenerative diseases and depression. Supported by Mitacs and Kapoose Creek Bio, Bhando's research focuses on natural drug discovery from fungi.
Defining the care pathway in patients with psoriasis and atopic dermat
A study explores the care pathway for psoriasis and atopic dermatitis, identifying strengths and weaknesses from both healthcare professionals (HCPs) and patients' perspectives. Patients often consult primary care or emergency departments initially, with referrals to dermatology services taking years. Effective treatments, including biologics, are available but access can be delayed. Follow-up phases show good communication but discrepancies in patient-reported outcome measures (PROMs) usage. Patients highlight long waiting times and treatment delays as needs, while HCPs note staffing shortages. The study concludes that optimizing the care pathway could improve patient outcomes.
Gilead's Livdelzi Seladelpar Demonstrated a Sustained Efficacy and Long Term Safety
Gilead Sciences announces 81% of PBC patients achieve durable biochemical response with Livdelzi by Month 30, with 41% achieving ALP normalization. Livdelzi also reduces pruritus severity, with 27% near resolution in moderate to severe cases. The safety profile remains robust, with no treatment-related SAEs reported.
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment
Soligenix opens patient enrollment for Phase 2 study DUS-AUBD-01, evaluating SGX945 (dusquetide) for Behçet's Disease treatment.
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the Treatment of Behçet's Disease
Soligenix initiates Phase 2 trial of SGX945 (dusquetide) for Behçet's Disease treatment, aiming to address unmet medical needs with a focus on severe ulcers. The open-label study will enroll 25 patients with mild to moderate Behçet's Disease, evaluating SGX945's efficacy in lesion clearance and quality of life. Dusquetide, an innate defense regulator, has shown promise in previous studies for oral mucositis and may offer significant relief for Behçet's Disease patients.
Exploring the Chronic Nature of Generalized Pustular Psoriasis
Podcast discusses generalized pustular psoriasis (GPP), a chronic, life-threatening inflammatory disease, with Dr. Boni Elewski and Dr. Mark G Lebwohl. They cover GPP's chronic symptoms, unpredictable flares, and the only approved treatment, spesolimab, which blocks IL-36 receptor signaling. The podcast emphasizes the need for early diagnosis, physician education, and long-term management guidelines to improve patient outcomes and quality of life.
Hidradenitis Suppurativa - Current Treatment - Treatment Algorithms: Claims Data Analysis
HS is a chronic inflammatory disorder affecting hair follicles, characterized by painful, fluid-filled lesions. Humira was the sole FDA-approved therapy until Cosentyx's approval in Oct 2023. Off-label treatments like antibiotics precede biologics. This analysis covers HS treatment trends, Humira's integration, patient progression rates, and therapy combinations, using real-world claims data.
Maze Therapeutics reports positive data from Phase I AKD treatment trial
Maze Therapeutics reports positive Phase I trial results for MZE829, a potential therapy for APOL1 kidney disease, showing it was well-tolerated with mild adverse events and dose-proportional pharmacokinetics, paving the way for a Phase II trial in 2025.
Maze Therapeutics Reports Positive First-in-Human Data From Phase 1 Healthy Volunteer
Maze Therapeutics announced positive Phase 1 results for MZE829, an APOL1 inhibitor for AKD, showing well-tolerated, dose-proportional pharmacokinetics supporting once-daily dosing. The data support advancing MZE829 into a planned Phase 2 trial in AKD patients, with anticipated initiation in Q1 2025.
Post hoc analysis of ESSENCE 1 trial highlights efficacy of 0.1% cyclosporine solution for ...
Dr. John Sheppard discusses post hoc analysis of ESSENCE 1 trial, evaluating 0.1% cyclosporine solution in a semifluorinated alkane vehicle for moderate dry eye. Results show 71% of patients responded positively, with 25% of MMP 9 positive patients becoming negative by day 28, indicating a valid clinical marker for inflammation resolution. This suggests steroid induction therapy may not be necessary, broadening the treatment's applicability to various dry eye patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath